

# Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study

Maria Khan<sup>1,\*</sup>, Haris Khan<sup>2</sup>, Shehriyar Khan<sup>3</sup> and Maimoona Nawaz<sup>4</sup>

## Abstract

**Introduction.** Coronavirus disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Corona Virus-2 (SARS-CoV-2). The disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing 2019–2020 corona virus pandemic. SARS-CoV-2 is closely related to the original SARS-CoV. It is thought to have a zoonotic origin. The virus is primarily spread between people during close contact, often via small droplets produced by coughing, sneezing or talking. People may also become infected by touching a contaminated surface and then touching their face. COVID-19 patients currently remain the primary source of infection. An epidemiological survey indicated that the general population is susceptible to SARS-CoV-2. The spectrum of this disease ranges from mild to life-threatening. Fever is the most common symptom, although older people and those with comorbidities may experience fever later in the disease. Other common symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, and muscle and joint pains. Symptoms such as nausea, vomiting and diarrhea have been observed in varying percentages. Some cases might progress promptly to acute respiratory distress syndrome (ARDS) and/or multiple organ function failure. Asymptomatic carriers and those in the incubation period may also be infectious.

**Aim.** To determine the epidemiological and clinical characteristics of patients presenting with COVID-19 at the screening clinic of a tertiary care hospital in Peshawar, Pakistan.

**Methodology.** In this descriptive study, we analysed data of patients presenting to a newly established Covid-19 screening clinic in Rehman Medical Institute. Anyone who reported with new onset fever and/or cough was tested for SARS-CoV-2 in the screening clinic. We documented and analysed demographic, epidemiological and clinical characteristics, which included age, sex, travel history, clinical features, comorbidities and laboratory data of patients confirmed by real-time reverse-transcription (RT)-PCR at Rehman Medical Institute, Peshawar, Pakistan from 15 March till 21 April 2020. Paired specimens of throat swabs and nasal swabs were obtained from 845 patients, ribonucleic acid (RNA) was extracted and tested for SARS-CoV-2 by the RT-PCR assay.

**Results.** A total of 845 specimens were taken as described above. The positive rate for SARS-CoV-2 was about 14.3%. Male and older population had a significantly higher positive rate. Of the 121 patients infected with SARS-CoV-2, the mean age was 43.19 years (sd, 17.57) and the infections were more frequent among male gender accounting for 85 (70.25%) patients. Common symptoms included fever (88 patients, 72%), cough (72 patients, 59.5%) and shortness of breath (69 patients, 57%). Twenty-two (18%) patients had recent travel history outside Pakistan in the previous 14 days, the majority of whom had returned back from Saudi Arabia.

**Conclusion.** In this single-centre, prospective, descriptive study, fever, cough and shortness of breath were the most common symptoms. Old age (>50 years), chronic underlying comorbidities and travel history may be risk factors. Therefore, we concluded that viral nucleic acid amplification tests (NAAT) played an important role in identifying SARS-CoV-2 infection in a screening clinic, which helped with isolation and cohorting of these patients.

## INTRODUCTION

In December 2019, a novel coronavirus, current reference name severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported from a cluster of patients with

pneumonia of unknown cause. This was linked to a local Huanan South China Seafood Market in Wuhan, Hubei Province, China [1]. The virus primarily causes an acute febrile illness, which can proceed to acute respiratory distress

syndrome (ARDS). The World Health Organization (WHO) named the disease COVID-19 [2–4]. On 30 January 2020, the WHO declared it a Public Health Emergency of International Concern (PHEIC) and on 11 April 2020 it was declared a pandemic [5]. At the time of this writing, the WHO estimates that COVID-19 has already been diagnosed in 3205726 people from 210 countries worldwide, claiming nearly 227290 deaths [6]. In Pakistan, there has been 15759 confirmed cases and 346 fatalities as of today.

The SARS-CoV-2 belongs to a family of viruses that may cause various symptoms such as pneumonia, fever, difficulty in breathing and pneumonitis [7]. The clinical manifestations include fever, cough, dyspnea, myalgia, fatigue, normal or decreased leukocyte counts and radiographic evidence of pneumonia. Organ dysfunction (such as shock, ARDS, acute cardiac injury and acute kidney injury) and death can occur in severe cases, yet severity seems to be associated with age, biological sex and comorbidities [3].

Full-genome sequencing and phylogenetic analysis indicated that SARS-Cov-2 was a distinct clade from the beta-coronaviruses associated with humans, in addition to the six known coronaviruses that infect humans: HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 and MERS-CoV [2]. It is closely similar to bat coronaviruses, with a homology of 85–96% to a bat SARS-like coronavirus (bat-SL-CoVZC45) at the whole-genome level [8] and it has been postulated that bats may be the primary source, nevertheless no specific animal association has been identified. At this present moment, the origin of SARS-Cov-2 is yet to be completely ascertained. SARS-CoV-2 has a single-stranded positive-sense RNA genome that is 26 to 32 kilobases in length, encoding 27 proteins including an RNA-dependent RNA polymerase (RdRP) and four structural proteins include the spike surface glycoprotein (S), nucleocapsid protein (N), small envelope protein (E) and matrix protein (M) [9, 10]. Conventional modes of transmission of SARS-CoV, MERS-CoV and highly pathogenic influenza consist of respiratory droplets [11], mechanisms that probably occur with SARS-CoV-2 as well. COVID-19 has been found to have higher levels of transmissibility and pandemic risk than the previous SARS-CoV, as the effective reproductive number (R) of COVID-19 (2.9) is estimated to be higher than the reported effective reproduction number (R) of SARS (1.77) at this early stage. Although, the average

incubation period of COVID-19 was initially estimated to be  $4.8 \pm 2.6$ , ranging from 2 to 11 days [9], currently guidelines from health authorities state an average incubation period of 7 days, ranging from 2 to 14 days [3].

Signs of Covid-19 infection overlap with other viral infections, which makes a clinical diagnosis very tricky. Diagnostic test based on detection of the viral sequence by real-time reverse-transcription (RT)-PCR is the gold standard confirmatory test [12]. People with positive SARS-CoV-2 RNA by respiratory tract specimens are probably an infectious source of COVID-19. The aim of our study was to analyse the epidemiological and clinical characteristics of patients with COVID-19 after diagnosis through detection of viral nucleic acid by RT-PCR.

## METHODOLOGY

The medical records and data from both outpatients and inpatients, with laboratory-confirmed Covid-19, as reported between 14 March 2020 and 21 April 2020, were collected. Covid-19 symptoms were diagnosed on the basis of the WHO interim guidance [13]. The selection criteria of the population group was based on, any patient presenting with new onset of fever, cough, headaches and body aches, were included in the study. A confirmed case of Covid-19 was defined as a positive result on real-time RT-PCR assay of nasal and oropharyngeal swab specimens [3]. All health-care workers caring for infected patients received comprehensive training and demonstrated competence in implementing infection control practices and procedures. Combined oropharyngeal and nasopharyngeal swab specimens in a single viral-transport medium tube were obtained under transmission based precautions from all patients presenting at the screening clinic. The procedure for collecting throat (oropharyngeal, OP) swabs entails swabbing the posterior pharynx and each tonsil area at least three times separately using a nylon-flocked swab, avoiding the tongue, and immediate placement of the swab into a sterile tube, containing 2–3 ml of viral transport media. All biological samples were sealed and transferred to the laboratory in strict accordance with the standard protocol.

This study was approved by the Ethics Committee of the Rehman Medical Institute, Peshawar and the need for informed consent was waived.

Received 08 May 2020; Accepted 25 June 2020; Published 12 August 2020

**Author affiliations:** <sup>1</sup>Department of Pathology, Rehman Medical Institute Peshawar, Pakistan; <sup>2</sup>Department of Diabetes and Endocrinology, Manchester University Hospitals NHS Foundation Trust, UK; <sup>3</sup>Department of Pediatrics, Maidstone and Tunbridge Wells NHS Trust, UK; <sup>4</sup>Department of Acute Medicine, The Christie NHS Foundation Trust, Manchester, UK.

\*Correspondence: Maria Khan, kmaria22@hotmail.com

**Keywords:** COVID-19; severe acute respiratory syndrome-related coronavirus 2; RT-PCR.

**Abbreviations:** ARDS, acute respiratory distress syndrome; Bat-SL-CoVZC45, Bat SARS-like coronavirus; COVID-19, Coronavirus disease 2019; Ct-value, cycle threshold value; HCoV-229E, human coronavirus 229E; HCoV-HKU1, human coronavirus HKU1; MERS-CoV, Middle East respiratory syndrome-related coronavirus; NAAT, nucleic acid amplification tests; PHEIC, Public Health Emergency of International Concern; RdRP, RNA-dependent RNA polymerase; RT-PCR, reverse transcriptase polymerase chain reaction; SARS-CoV-2, Severe Acute Respiratory Corona Virus-2; WHO, World Health Organization.

The data used to support the findings of this study are included within the article.

## Laboratory confirmation

A real-time RT-PCR, a commercial assay in accordance with the manufacturer's instructions, was used for the quantitative detection of ribonucleic acid from SARS-CoV-2 (Primerdesign COVID-19 genesig Real-Time PCR assay), which was in nasal and oropharyngeal swab specimens from patients suspected of COVID-19. The product contains oligonucleotide primers and dual-labelled hydrolysis probes (TaqMan Technology), as well as control material, along with manual nucleic acid extraction. (MasterPure Complete DNA and RNA Purification Kit, Lucigen). The oligonucleotide primers and probe for the detection of SARS-CoV-2 were selected from the orf1 ab genome region and also targeting RNA-dependent RNA polymerase –RdRp. RNA extracted and purified from nasal and oropharyngeal swabs was reverse transcribed to cDNA and subsequently amplified using real-time PCR instruments: Roche LightCycler 480 II (software version 1.5). Conditions for amplifications were 50 °C for 15 min, 95 °C for 3 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 30 s. The concentration of 0.33 copies/µl of SARS-CoV-2 whole-viral-genome RNA was the limit of detection of this assay. Specimens were processed and results were dispatched within 6–8 h, if delay was expected then specimens were stored at 2–8 °C for up to 72 h after collection. The extracted nucleic acid was stored at –70 °C in a freezer for long-term storage. To ensure the integrity and verification of RT-PCR assay results, an internal control was analysed in parallel for each patient sample, as well as testing one replicate of the positive control and one replicate of the negative control in each batch. A cycle threshold value (Ct-value) less than 37 was defined as a positive test result, and a Ct-value of 40 or more was defined as a negative test result. A medium load, defined as a Ct-value of 37 to less than 40, required confirmation by retesting. Each control was processed as a sample, through nucleic acid isolation and amplification/detection. Controls results (detection cycle or Ct) were generated for the two SARS-CoV-2 targets, and the internal control target. Acceptable control results for the SARSCoV-2 and internal control were required for the run to be acceptable.

## Statistical analysis

Continuous variables were expressed as medians and interquartile ranges or simple ranges, as appropriate. Categorical variables were summarized as counts and percentages. No imputation was made for missing data. Because the cohort of patients in our study was not derived from random selection, all statistics are deemed to be descriptive only. All analyses were performed using SPSS 22.0.

## RESULTS

From 15 March to 21 April 2020, 845 cases were tested in the screening clinic for SARS-CoV-2 infection in Rehman Medical Institute, Peshawar, who were suspected or at high risk of infection because of (1) typical respiratory infection symptoms such as new onset fever or cough, or (2) close contact with a SARS-CoV-2 patient. Among those undergoing

SARS-CoV-2 RT-PCR testing, 601 were male (71.12%), 244 were female (28.88%). Groups based on age: 0–9 ( $n=18$ ), 10–19 ( $n=45$ ), 20–29 ( $n=225$ ), 30–39 ( $n=222$ ), 40–49 ( $n=123$ ), 50–59 ( $n=107$ ), 60–69 ( $n=68$ ), 70–79 ( $n=24$ ), 80–89 ( $n=10$ ), 90–99 ( $n=3$ ).

Out of 845 patients, 121 (14.3%) were SARS-CoV-2 RT-PCR positive, 85 (70.25%) were male while 36 (29.8%) were female. When we analysed the positive rate between male and female cases from the screening clinic, a significant difference ( $P<0.01$ ) was observed. The data in age-based groups at the screening clinic, the older (>50 years) patients had a higher positive rate. The median age of the patients was 47 years (interquartile range, 4 to 90); 107 (88.43%) patients were in the age range of 20 and 69 years (Fig. 1)

Among the reported symptoms, fever was present in 72.7% of the patients on arrival at the screening clinic. The second most common symptom was cough (59.5%) (Table 1).


Among the overall positive cases, 39.6% had one of the comorbidities, as shown in Table 2.

Amongst positive cases, 12 (9.9%) were healthcare workers (doctors=8; nurses=3; and paramedics=1). Out of 121 positive cases, 35 (28.9%) had contact with known Covid-19 cases at home or in the community; the rest, 86 (71%), were not sure about their contact history. Among 121 cases, 25 (20.6%) travelled intercity and 22 (18%) had arrived from other countries in the past 14 days. Saudi Arabia (8), Iran (3), Dubai (3), USA (3), UK (3), Germany (1) and Malaysia (1) (Table 3).

## DISCUSSION

The epidemic started in Pakistan with multiple imported cases throughout the country, mostly from Iran, Saudi Arabia and Europe. Pakistan reported its first case on 26 February 2020, a patient who travelled with his family from Iran to Karachi, Pakistan. The province of Khyber-Pakhtunkhwa has reported almost 1984 SARS-CoV-2 positive cases and 104 deaths at this point. Our institute has reported 121 cases out of a total 845 patients tested in the past 1 month, contributing a positivity rate of 14.3% in the tested cohort. In our research, the majority of the positive cases were between 25 to 60 years old, which is similar to previous studies [4]. Some studies have reported a majority age distribution of patients between 25 and 89 years [14] and there have been fewer identified cases among children and infants [15]. Only five positive cases of less than 10 years of age were found in our study (%). The median age of patients in our study was 47 years, which was comparable to the median age of cases in Wuhan reported by Cao [3] and Zhang [16], which were 49.0 and 55.5 years, respectively.

Generally, it was suggested that individuals at risk were mostly immunocompromised, in this case, elderly and those with renal, cardiovascular and hepatic dysfunction [17]. In our study, predominantly male (70.25%) population were infected, analogous to meta-analysis by Yang *et al.* [18]. The proportional male to female (M:F) death ratio in confirmed



**Fig. 1.** Age range among patients presenting to the screening clinic of Rehman Medical Institute, Peshawar.

cases is higher in all the countries with available data. Whereas, it is customary to think women are less likely to be infected than men, partly because of their more robust innate and adaptive immune responses [19]. There may be other behavioural and social differences that favour women, with prior studies suggesting women are more likely than men to follow hand-hygiene practices [20] and seek preventive care [21].

Subsequently, 34 (28%) patients had family members in the same household, also SARS-CoV-2 positive. These findings echo the latest reports, including the outbreak

of a family cluster [22], and transmission from an asymptomatic patient [23]. Thus early detection and timely isolation is vital before a single case becomes a cluster. It also raises the concern that the risks and benefits should be considered in home quarantine for confirmed cases, which could result in family case clusters if they transmit the virus to other members of the same household. During the initial phase of the Covid-19 outbreak, the diagnosis of the disease was complicated by the diversity in symptoms, the imaging findings and the severity of disease at the time of presentation. The absence of fever in Covid-19 is more frequent than in SARS-CoV (1%) and MERS-CoV infection (2%). Afebrile patients may be missed if the surveillance case definition focuses on fever detection only [24]. The symptoms of COVID-19 are similar

**Table 1.** Clinical features of SARS-CoV-2 positive cases

Signs and symptoms of SARS-COV-2 (n=121) cases n (%)	
Fever	88 (72.7%)
Cough	72 (59.5%)
Shortness of breath	69 (57%)
Muscle ache	57 (47.1%)
Sore throat	44 (36.3%)
Headache	38 (31.4%)
Diarrhea	21 (17.35%)
Nausea and vomiting	15 (12.4%)
Combined fever, cough and shortness of breath	12 (9.9%)

**Table 2.** Comorbidities present among SARS-CoV-2 positive cases

Comorbidity among SARS-COV-2 (n=121) cases	n (%)
Hypertension	15 (12.3%)
Diabetes mellitus	13 (10.7%)
Cardiovascular and cerebrovascular diseases	9 (7.4%)
Asthma	7 (5.7%)
HBV, HCV or HIV infection	3 (2.5%)
Malignant tumours	1 (0.8%)
More than one comorbidities	6 (4.9%)

**Table 3.** Demographic characteristic, Travel history and contact history of SARS-COV-2 (n=121) positive cases

Gender	Age (years)	Specimen collection date	Travel history in past 14 days (inside country/intercity)	Travel history in past 14 days (outside country)	Contact with Covid-19 positive case in past 14 days
Male	65	21/Apr/2020	-	-	Yes
Male	26	21/Apr/2020	-	-	Not known
Male	9	21/Apr/2020	-	-	Yes
Male	63	21/Apr/2020	-	-	Yes
Male	67	20/Apr/2020	-	-	Yes
Female	15	20/Apr/2020	-	-	Yes
Female	5	20/Apr/2020	-	-	Yes
Male	50	20/Apr/2020	-	-	Not known
Female	5	20/Apr/2020	-	-	Yes
Male	55	20/Apr/2020	-	-	Not known
Male	50	20/Apr/2020	-	-	Yes
Male	26	20/Apr/2020	-	-	Not known
Female	23	20/Apr/2020	-	-	Not known
Male	55	20/Apr/0020	-	-	Yes
Male	33	19/Apr/2020	-	-	Not known
Male	19	19/Apr/2020	-	-	Yes
Female	22	19/Apr/2020	-	-	Not known
Male	35	19/Apr/2020	-	-	Not known
Male	60	18/Apr/2020	Kohat	-	Yes
Female	55	18/Apr/2020	-	-	Not known
Male	63	18/Apr/2020	-	-	Not known
Male	36	18/Apr/2020	-	-	Yes
Female	38	18/Apr/2020	-	-	Yes
Male	25	18/Apr/2020	-	-	Not known
Male	37	17/Apr/2020	Kohat	-	Yes
Male	34	17/Apr/2020	-	-	Not known
Male	44	17/Apr/2020	-	-	Yes
Male	81	17/Apr/2020	-	-	Not known
Male	48	17/Apr/2020	-	-	Not known
Male	25	17/Apr/2020	-	-	Not known
Male	50	17/Apr/2020	Kohat	-	Not known
Male	24	16/Apr/2020	-	-	Yes
Male	70	16/Apr/2020	-	-	Not known
Male	19	16/Apr/2020	-	-	Not known
Male	45	16/Apr/2020	Raiwind (Lahore)	-	Not known
Female	57	16/Apr/2020	-	-	Yes
Male	47	16/Apr/2020	-	-	Yes

Continued

Table 3. Continued

Gender	Age (years)	Specimen collection date	Travel history in past 14 days (inside country/intercity)	Travel history in past 14 days (outside country)	Contact with Covid-19 positive case in past 14 days
Male	37	15/Apr/2020	-	-	Yes
Male	9	15/Apr/2020	-	-	Not known
Male	4	15/Apr/2020	-	-	Yes
Male	65	15/Apr/2020	-	-	Not known
Male	28	15/Apr/2020	Raiwind (Lahore)	-	Not known
Female	29	15/Apr/2020	-	-	Yes
Male	32	15/Apr/2020	-	-	Yes
female	25	15/Apr/2020	-	-	Yes
Male	28	15/Apr/2020	-	-	Yes
Male	65	14/Apr/2020	-	-	Not known
Male	50	14/Apr/2020	Raiwind (Lahore)	-	Not known
Female	60	14/Apr/2020	-	-	Not known
Male	58	14/Apr/2020	-	-	Yes
Female	20	14/Apr/2020	-	-	Not known
Female	45	13/Apr/2020	-	-	Yes
Male	30	13/Apr/2020	Karachi	-	Not known
Male	52	13/Apr/2020	Raiwind (Lahore)	-	Not known
Female	53	13/Apr/2020	-	-	Not known
Female	17	13/Apr/2020	-	-	Yes
Female	36	12/Apr/2020	-	-	Yes
Female	38	12/Apr/2020	-	-	Yes
Female	67	12/Apr/2020	-	-	Yes
Male	31	11/Apr/2020	-	-	Yes
Male	58	11/Apr/2020	-	-	Not known
Male	28	11/Apr/2020	Raiwind (Lahore)	-	Not known
Male	30	10/Apr/2020	-	-	Not known
Female	30	10/Apr/2020	-	-	Yes
Female	24	10/Apr/2020	-	-	Not known
Male	55	10/Apr/2020	-	-	Not known
Female	65	10/Apr/2020	-	-	Not known
Female	65	10/Apr/2020	Kohat	-	Not known
Male	42	09/Apr/2020	-	-	Yes
Female	60	09/Apr/2020	-	-	Not known
Male	26	09/Apr/2020	Raiwind (Lahore)	-	Not known
Male	90	09/Apr/2020	-	-	Not known
Female	15	08/Apr/2020	-	-	Yes
Male	62	08/Apr/2020	-	-	Not known

Continued



Table 3. Continued

Gender	Age (years)	Specimen collection date	Travel history in past 14 days (inside country/intercity)	Travel history in past 14 days (outside country)	Contact with Covid-19 positive case in past 14 days
Male	54	08/Apr/2020	Raiwind (Lahore)	–	Not known
Female	38	08/Apr/2020	–	–	Not known
Male	70	08/Apr/2020	–	Saudi Arabia	Not known
Male	52	07/Apr/2020	–	Saudi Arabia	Not known
Male	62	07/Apr/2020	–	–	Not known
Male	70	06/Apr/2020	–	–	Not known
Male	32	06/Apr/2020	Raiwind (Lahore)	–	Not known
Male	44	06/Apr/2020	–	–	Not known
Male	46	05/Apr/2020	–	Saudi Arabia	Not known
Male	63	05/Apr/2020	–	–	Not known
Male	63	05/Apr/2020	–	–	Not known
Male	24	05/Apr/2020	Raiwind (Lahore)	–	Not known
Male	60	05/Apr/2020	–	Iran	Not known
Female	12	04/Apr/2020	Kohat	–	Yes
Male	67	04/Apr/2020	–	–	Not known
Female	61	04/Apr/2020	–	Dubai	Not known
Female	55	04/Apr/2020	–	Saudi Arabia	Not known
Male	47	03/Apr/2020	–	Dubai	Not known
Male	55	02/Apr/2020	Dera Ismail Khan	–	Not known
Female	45	02/Apr/2020	–	–	Not known
Male	30	02/Apr/2020	–	United States of America	Not known
Male	44	02/Apr/2020	–	Iran	Not known
Male	44	02/Apr/2020	–	United Kingdom	Not known
Male	32	02/Apr/2020	Raiwind (Lahore)	–	Not known
Male	47	01/Apr/2020	Raiwind (Lahore)	–	Not known
Male	65	01/Apr/2020	–	–	Not known
Female	45	01/Apr/2020	–	Iran	Not known
Male	65	01/Apr/2020	–	Saudi Arabia	Not known
Male	52	01/Apr/2020	–	–	Not known
Male	60	31/Mar/2020	Karachi	–	Not known
Female	63	31/Mar/2020	–	Saudi Arabia	Not known
Female	38	31/Mar/2020	–	–	Not known
Female	25	30/Mar/2020	–	United Kingdom	Not known
Male	30	30/Mar/2020	–	Dubai	Not known
Male	31	30/Mar/2020	Raiwind (Lahore)	–	Not known
Male	45	29/Mar/2020	Raiwind (Lahore)	–	Not known
Male	52	29/Mar/2020	–	United States of America	Not known

Continued

Table 3. Continued

Gender	Age (years)	Specimen collection date	Travel history in past 14 days (inside country/intercity)	Travel history in past 14 days (outside country)	Contact with Covid-19 positive case in past 14 days
Female	50	29/Mar/2020	–	Saudi Arabia	Not known
Male	52	29/Mar/2020	Karachi		Not known
Male	45	29/Mar/2020		Saudi Arabia	Not known
Female	41	30/Mar/2020		Germany	Not known
Male	36	30/Mar/2020	Kohat		Not known
Male	39	29/Mar/2020	Dera Ismail Khan		Not known
Male	39	28/Mar/2020	–	United Kingdom	Not known
Male	29	24/Mar/2020	–	Malaysia	Not known
Male	38	18/Mar/2020	Karachi		Not known
Female	59	15/Mar/2020	–	United States of America	Not known

to influenza (e.g. fever, cough or fatigue) and outbreaks will usually occur during the time of the year with high incidence of respiratory diseases caused by influenza, respiratory syncytial virus and other respiratory viruses. Vaccines can still be useful in prevention from influenza and will reduce possible confusion with the COVID-19 infection [25]. Contrary to a study in India where almost half (42.9%) of the patients were asymptomatic [26], we reported only 23% such cases.

In line with recent studies [16, 17], we found fever (72%) and cough (59.5%) were the dominant symptoms; gastrointestinal symptoms (17.35%) were uncommon, which suggests a difference in viral tropism as compared with SARS-CoV, MERS-CoV and seasonal influenza [27]. These findings have important implications for patient triage and hospital risk zoning. Moreover, fever was more prevalent in patients in the 20–49 age group while cough was more common in patients aged 40 to 79 years. Children aged 1 to 19 usually presented with diarrhea. In one hospital in mainland China, 15 medical workers were reported with COVID-19, 14 of whom were assumed to have been infected by the same patient [28], comparable to our findings of 12 healthcare workers infected during the study time period, but we could not ascertain the source of their infection accurately. Outpatient medical staff could be at higher risk when encountering suspected COVID-19 patients, thus more aggressive PPE protection and proactive patient screening is necessary.

Wang *et al.* [4] reported findings from 138 cases of COVID-19 among which 64 (46.4%) had comorbidities. Similarly the prevalence of comorbidities was 38% in our study, including hypertension (12.3%), diabetes (10.7%), cardiovascular and cerebrovascular diseases (9%) and asthma (7%) that was consistent with the prevalence of hypertension and diabetes in Chinese COVID-19 studies, which stood at 23.2% [29] and 10.9% respectively [30] in adults.

Our findings also suggested that the modes of transmission have changed considerably with the spread of the disease. A large proportion of early reported cases were travellers from both abroad (18.1%) and inside the country (20.66%). Among imported cases, they were mostly from countries with high community transmissions. None of the cases in Peshawar had a history of travel from mainland China.

Since RT-PCR is one of the most quickly established laboratory diagnostic method in the COVID-19 pandemic, it served efficiently as a modality to provide us with a result within 2–4 h. However, some investigators and clinicians argued that computed tomography (CT) imaging can be a better modality in identifying the SARS-CoV-2 infection instead, since quite a few severe cases showed progressive multiple peripheral ground-glass opacities in both lungs even when the RT-PCR results were negative [31]. Based on the reasons mentioned above, we suggest that viral NAAT is reliable and widely used laboratory diagnosis for SARS-CoV-2 infection, especially for screening clinics. Clinical characteristics, chest imaging and etiology testing based on viral genes RT-PCR should be used in making a diagnosis [16]. The rising number of cases and mortality risk estimates are demonstrating the dire need for enhanced public health mediations, good hygienic conditions, social distancing and movement limitations to control the COVID-19 pandemic.

## CONCLUSION

The COVID-19 pandemic is a global health emergency that has changed the world in an unprecedented way. It is spreading rapidly throughout the world, including Pakistan, causing varying degrees of illness. Patients mostly presented with fever, cough and shortness of breath and a good proportion of positive cases (23%) were asymptomatic. The disease has shown a wide spectrum of severity in various studies published so far. Close monitoring and



large-scale quarantine and cohorting strategies will be needed to prevent widespread transmission within the community.

There has been a rapid surge in research in response to the outbreak of COVID-19. During this early period, published research has primarily explored the epidemiology, causes, clinical manifestation and laboratory diagnosis. We suggest that both nasopharyngeal and oropharyngeal swabs test for SARS-CoV-2 RNA should be performed to reduce the false-negative rate. More tests, more specimens, and more methods could be considered. Treatment and management options are still in the very early phases of clinical trials.

## Limitations

Our study has some notable limitations. First, some cases had incomplete documentation of the exposure history and the variation in the structure of electronic databases among different participating sites and the urgent timeline for data extraction. Since our study was limited by a lack of critically ill patients, more detailed information, such as the final prognosis of patients, could not be obtained.

## Funding information

The authors received no specific grant from any funding agency.

## Acknowledgements

We thank all the patients who consented to this study, and the frontline healthcare professionals who are involved in patient care during this pandemic.

## Author contributions

M.K. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. H.K., S.K. and M.N. contributed equally as co-authors. M.K.: conceptualized and designed the study, methodology, collected data, and revised the manuscript. H.K.: acquisition, statistical analysis, reviewed and revised the manuscript. S.K.: conceptualization, writing – original draft, interpretation of data, critically reviewed the manuscript for important intellectual content. M.N.: administrative, technical, or material support, reviewed and revised the manuscript.

## Conflicts of interest

The authors declare that there are no conflicts of interest.

## Ethical statement

Ethical approval was obtained from institutional ethical approval review board before start of the study. Written informed as well as oral consent was taken from the subjects. Consent for publication was taken from institution as well as all authors of the manuscript. Informed consent was obtained from all individuals included in this study.

## References

- China Wuhan Municipal Health Commission. Wuhan Municipal Health Commission briefing on the pneumonia epidemic situation 31 Dec 2019 [in Chinese]. 2020 [cited 2020 Feb 20]. <http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989>.
- Zhu N, Zhang D, Wang W, Li X, Yang B et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727–733.
- Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
- Wang D, Hu B, Hu C, Zhu F, Liu X et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–1069.
- Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed* 2020;91:157–160.
- World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 98. 2020 [cited 2020 Apr 27]. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>.
- WMHC. Wuhan Municipal Health and Health Commission's Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020. <http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989>. Accessed 1 Feb 2020.
- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579:270–273.
- Wu A, Peng Y, Huang B, Ding X, Wang X et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. *Cell Host Microbe* 2020;27:325–328.
- Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB et al. Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. *J Virol* 2016;90:7415–7428.
- Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect* 2016;92:235–250.
- Jeong JH, Kim KH, Jeong SH, Park JW, Lee SM et al. Comparison of sputum and nasopharyngeal swabs for detection of respiratory viruses. *J Med Virol* 2014;86:2122–2127.
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. January 28, 2020.
- Da R, Showkat A, Sa R, Ma M. The Covid-19 pandemic: a study of the current evidence in India. Purakala with Issn 0971-2143. *Is An Ugc Care Journal* 2020 Apr 14;31:1–6.
- Wang C, Prevalence WX. Nosocomial infection and psychological prevention of novel coronavirus infection. *Chin General Pract Nurs* 2020;18:2–3.
- Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507–513.
- Li Q, Guan X, Wu P, Wang X, Zhou L et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020;382:1199–1207.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Inf Dis* 2020.
- Jailton S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. *Clin Rev Allergy Immunol* 2019;56:308–321.
- Johnson HD, Sholcosky D, Gabello K, Ragni R, Ogonosky N. Sex differences in public restroom handwashing behavior associated with visual behavior prompts. *Percept Mot Skills* 2003;97:805–810.
- Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. *J Fam Pract* 2000;49:147–152.
- Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;395:514–523.
- Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *N Engl J Med* 2020;382:970–971.
- Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *The Lancet* 2015;386:995–1007.
- Patel A, Jernigan DB, 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December

- 31, 2019-February 4, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:140–146.
26. Gupta N, Agrawal S, Ish P, Mishra S, Gaiind R *et al.* Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. *Monaldi Arch Chest Dis* 2020 Apr 10;90.
27. Leung WK, To K-F, Chan PKS, Chan HLY, Wu AKL *et al.* Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. *Gastroenterology* 2003;125:1011–1017.
28. Chinese Academy of Sciences. Wuhan coronavirus has strong ability to infect humans. Press release. Jan 21 2020.
29. Hu S, Gao R, Liu L, ZHU M, WANG W *et al.* Summary of the 2018 report on cardiovascular diseases in China. *Chin Circulation J* 2019;34:209.
30. Liu M, Liu S-W, Wang L-J, Bai Y-M, Zeng X-Y *et al.* Burden of diabetes, hyperglycaemia in China from to 2016: findings from the 1990 to 2016, global burden of disease study. *Diabetes Metab* 2019;45:286–293.
31. Fang Y, Zhang H, Xie J, Lin M, Ying L *et al.* Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology* 2020:200432.

**Five reasons to publish your next article with a Microbiology Society journal**

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

**Find out more and submit your article at [microbiologyresearch.org](http://microbiologyresearch.org).**